When.com Web Search

  1. Ads

    related to: hemophilia b treatment drugs over the counter products canada

Search results

  1. Results From The WOW.Com Content Network
  2. Etranacogene dezaparvovec - Wikipedia

    en.wikipedia.org/wiki/Etranacogene_dezaparvovec

    The safety and effectiveness of etranacogene dezaparvovec were evaluated by the US Food and Drug Administration (FDA) in two studies of 57 adult men 18 to 75 years of age with severe or moderately severe hemophilia B. [7] Effectiveness was established based on decreases in the men's annualized bleeding rate (ABR). [7]

  3. Fidanacogene elaparvovec - Wikipedia

    en.wikipedia.org/wiki/Fidanacogene_elaparvovec

    In the US, fidanacogene elaparvovec is indicated for the treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis therapy; or have current or historical life-threatening hemorrhage; or have repeated, serious spontaneous bleeding episodes; and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var ...

  4. Concizumab - Wikipedia

    en.wikipedia.org/wiki/Concizumab

    Concizumab, sold under the brand name Alhemo, is a monoclonal antibody used for the treatment of hemophilia A and hemophilia B. [5] [8] It is an anti-tissue factor pathway inhibitor. [5] [8] The most common adverse reactions include injection site reactions and hives (urticaria). [11]

  5. Gene therapy cures patients with hemophilia B - AOL

    www.aol.com/gene-therapy-cures-patients...

    Some current treatments for the condition involve repeated infusions of the protein. But new research shows a one-time gene therapy could offer long-term efficacy for patients. ... Hemophilia B is ...

  6. Hemophilia B Treatment Market Surges with 7.6% CAGR, set to ...

    lite.aol.com/tech/story/0022/20241125/9277823.htm

    The global hemophilia B treatment market is growing rapidly, powered by gene therapy innovations, extended half-life factor IX products, and an increased concentration on personalized care. The industry players can make the most of the advanced therapeutic developments of Hemgenix, a gene therapy approved by the FDA, and recombinant factor IX ...

  7. FDA Approves Pfizer's Second Hemophilia Drug With Six Months

    www.aol.com/fda-approves-pfizers-second...

    Hympavzi is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered via

  1. Ads

    related to: hemophilia b treatment drugs over the counter products canada